Shares of STAAR Surgical (NASDAQ:STAA - Get Free Report) rose 7.7% during mid-day trading on Monday . The company traded as high as $19.82 and last traded at $19.75. Approximately 212,078 shares traded hands during trading, a decline of 80% from the average daily volume of 1,086,151 shares. The stock had previously closed at $18.34.
Wall Street Analyst Weigh In
STAA has been the subject of a number of research analyst reports. Piper Sandler lowered their price objective on shares of STAAR Surgical from $40.00 to $16.00 and set a "neutral" rating for the company in a research report on Wednesday, February 12th. William Blair cut shares of STAAR Surgical from an "outperform" rating to a "market perform" rating in a research report on Wednesday, February 12th. Stifel Nicolaus decreased their price target on shares of STAAR Surgical from $38.00 to $20.00 and set a "buy" rating for the company in a research report on Wednesday, February 12th. Needham & Company LLC restated a "hold" rating on shares of STAAR Surgical in a research report on Thursday, February 27th. Finally, Mizuho cut shares of STAAR Surgical from an "outperform" rating to a "neutral" rating and decreased their price target for the company from $45.00 to $17.00 in a research report on Wednesday, February 12th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $26.86.
View Our Latest Stock Report on STAA
STAAR Surgical Stock Performance
The stock's 50 day moving average price is $20.69 and its 200 day moving average price is $26.38. The company has a market capitalization of $858.01 million, a P/E ratio of -42.50 and a beta of 0.66.
Insider Buying and Selling
In other STAAR Surgical news, major shareholder Broadwood Partners, L.P. acquired 259,616 shares of STAAR Surgical stock in a transaction dated Wednesday, February 12th. The stock was purchased at an average cost of $14.96 per share, for a total transaction of $3,883,855.36. Following the completion of the acquisition, the insider now directly owns 11,137,623 shares of the company's stock, valued at $166,618,840.08. This represents a 2.39 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders have purchased a total of 910,843 shares of company stock valued at $15,509,972 over the last ninety days. 1.00% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the business. Broadwood Capital Inc. grew its holdings in shares of STAAR Surgical by 0.7% during the fourth quarter. Broadwood Capital Inc. now owns 10,848,631 shares of the medical instruments supplier's stock valued at $263,513,000 after buying an additional 80,200 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of STAAR Surgical by 5.8% during the fourth quarter. Vanguard Group Inc. now owns 5,855,570 shares of the medical instruments supplier's stock valued at $142,232,000 after buying an additional 319,441 shares during the last quarter. State Street Corp grew its holdings in shares of STAAR Surgical by 0.5% during the third quarter. State Street Corp now owns 1,940,567 shares of the medical instruments supplier's stock valued at $72,092,000 after buying an additional 10,430 shares during the last quarter. Resona Asset Management Co. Ltd. acquired a new position in shares of STAAR Surgical during the fourth quarter valued at about $36,411,000. Finally, Geode Capital Management LLC grew its holdings in shares of STAAR Surgical by 2.7% during the third quarter. Geode Capital Management LLC now owns 1,174,499 shares of the medical instruments supplier's stock valued at $43,641,000 after buying an additional 31,212 shares during the last quarter. 96.70% of the stock is currently owned by institutional investors and hedge funds.
About STAAR Surgical
(
Get Free Report)
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.
Featured Stories
Before you consider STAAR Surgical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and STAAR Surgical wasn't on the list.
While STAAR Surgical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
